These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 29768713)

  • 1. Clinical Drug-Drug Interaction Potential of BFE1224, Prodrug of Antifungal Ravuconazole, Using Two Types of Cocktails in Healthy Subjects.
    Ishii Y; Ito Y; Matsuki S; Sanpei K; Ogawa O; Takeda K; Schuck EL; Uemura N
    Clin Transl Sci; 2018 Sep; 11(5):477-486. PubMed ID: 29768713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies.
    Zurth C; Koskinen M; Fricke R; Prien O; Korjamo T; Graudenz K; Denner K; Bairlein M; von Bühler CJ; Wilkinson G; Gieschen H
    Eur J Drug Metab Pharmacokinet; 2019 Dec; 44(6):747-759. PubMed ID: 31571146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential of Ravuconazole and its Prodrugs as the New OralTherapeutics for Onychomycosis.
    Yamaguchi H
    Med Mycol J; 2016; 57(4):E93-E110. PubMed ID: 27904057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Drug properties of fosravuconazole L-lysine ethanolate (NAILIN
    Nakano M; Aoki Y; Yamaguchi H
    Nihon Yakurigaku Zasshi; 2019; 153(2):79-87. PubMed ID: 30745518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Napabucasin Drug-Drug Interaction Potential, Safety, Tolerability, and Pharmacokinetics Following Oral Dosing in Healthy Adult Volunteers.
    Dai X; Karol MD; Hitron M; Hard ML; Goulet MT; McLaughlin CF; Brantley SJ
    Clin Pharmacol Drug Dev; 2021 Aug; 10(8):824-839. PubMed ID: 34107166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphonooxymethyl prodrugs of the broad spectrum antifungal azole, ravuconazole: synthesis and biological properties.
    Ueda Y; Matiskella JD; Golik J; Connolly TP; Hudyma TW; Venkatesh S; Dali M; Kang SH; Barbour N; Tejwani R; Varia S; Knipe J; Zheng M; Mathew M; Mosure K; Clark J; Lamb L; Medin I; Gao Q; Huang S; Chen CP; Bronson JJ
    Bioorg Med Chem Lett; 2003 Nov; 13(21):3669-72. PubMed ID: 14552754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of rolapitant administered orally on the pharmacokinetics of dextromethorphan (CYP2D6), tolbutamide (CYP2C9), omeprazole (CYP2C19), efavirenz (CYP2B6), and repaglinide (CYP2C8) in healthy subjects.
    Wang J; Zhang ZY; Lu S; Powers D; Kansra V; Wang X
    Support Care Cancer; 2019 Mar; 27(3):819-827. PubMed ID: 30084103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of Pharmacokinetic Interactions Between Obeticholic Acid and Caffeine, Midazolam, Warfarin, Dextromethorphan, Omeprazole, Rosuvastatin, and Digoxin in Phase 1 Studies in Healthy Subjects.
    Edwards JE; Eliot L; Parkinson A; Karan S; MacConell L
    Adv Ther; 2017 Sep; 34(9):2120-2138. PubMed ID: 28808886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and nonclinical and clinical pharmacokinetics of PC945, a novel inhaled triazole antifungal agent.
    Cass L; Murray A; Davis A; Woodward K; Albayaty M; Ito K; Strong P; Ayrton J; Brindley C; Prosser J; Murray J; French E; Haywood P; Wallis C; Rapeport G
    Pharmacol Res Perspect; 2021 Feb; 9(1):e00690. PubMed ID: 33340279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Comprehensive In Vivo and In Vitro Assessment of the Drug Interaction Potential of Red Ginseng.
    Seong SJ; Kang WY; Heo JK; Jo J; Choi WG; Liu KH; Lee S; Choi MK; Han YH; Lee HS; Ohk B; Lee HW; Song IS; Yoon YR
    Clin Ther; 2018 Aug; 40(8):1322-1337. PubMed ID: 30078466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
    Walzer M; Bekersky I; Blum RA; Tolbert D
    Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic Effects of Isavuconazole Coadministration With the Cytochrome P450 Enzyme Substrates Bupropion, Repaglinide, Caffeine, Dextromethorphan, and Methadone in Healthy Subjects.
    Yamazaki T; Desai A; Goldwater R; Han D; Howieson C; Akhtar S; Kowalski D; Lademacher C; Pearlman H; Rammelsberg D; Townsend R
    Clin Pharmacol Drug Dev; 2017 Jan; 6(1):54-65. PubMed ID: 27273149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Compartmental pharmacokinetics and tissue distribution of the antifungal triazole ravuconazole following intravenous administration of its di-lysine phosphoester prodrug (BMS-379224) in rabbits.
    Groll AH; Mickiene D; Petraitis V; Petraitiene R; Kelaher A; Sarafandi A; Wuerthwein G; Bacher J; Walsh TJ
    J Antimicrob Chemother; 2005 Nov; 56(5):899-907. PubMed ID: 16172108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Use of Transporter Probe Drug Cocktails for the Assessment of Transporter-Based Drug-Drug Interactions in a Clinical Setting-Proposal of a Four Component Transporter Cocktail.
    Ebner T; Ishiguro N; Taub ME
    J Pharm Sci; 2015 Sep; 104(9):3220-8. PubMed ID: 25981193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adults.
    Ma JD; Nafziger AN; Villano SA; Gaedigk A; Bertino JS
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1130-5. PubMed ID: 16569820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".
    Streetman DS; Bleakley JF; Kim JS; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
    Clin Pharmacol Ther; 2000 Oct; 68(4):375-83. PubMed ID: 11061577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pomalidomide: evaluation of cytochrome P450 and transporter-mediated drug-drug interaction potential in vitro and in healthy subjects.
    Kasserra C; Assaf M; Hoffmann M; Li Y; Liu L; Wang X; Kumar G; Palmisano M
    J Clin Pharmacol; 2015 Feb; 55(2):168-78. PubMed ID: 25159194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I/II randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis.
    Gupta AK; Leonardi C; Stoltz RR; Pierce PF; Conetta B;
    J Eur Acad Dermatol Venereol; 2005 Jul; 19(4):437-43. PubMed ID: 15987289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytochrome P450 3A Induction Predicts P-glycoprotein Induction; Part 1: Establishing Induction Relationships Using Ascending Dose Rifampin.
    Lutz JD; Kirby BJ; Wang L; Song Q; Ling J; Massetto B; Worth A; Kearney BP; Mathias A
    Clin Pharmacol Ther; 2018 Dec; 104(6):1182-1190. PubMed ID: 29569723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.
    Krishna G; Moton A; Ma L; Savant I; Martinho M; Seiberling M; McLeod J
    Clin Ther; 2009 Feb; 31(2):286-98. PubMed ID: 19302901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.